This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: Hematology, Subject name: Pharmacology
[{'content': 'RAVULIZUMAB is a new drug approved for treatment of? \nSelect and explain. \nA. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, B. SICKLE CELL ANEMIA, C. ACUTE HEPATIC PROPHYRIA, D. MENINGOCOCCAL INFECTIONS', 'role': 'user'}, {'content': 'Answer: A \nExplanation: RAVULIZUMAB : It is monoclonal antibody against C5 complement component. PNH is a rare acquired disorder that leads to hemolysis. Ravulizumab is a longest acting complement inhibitor that prevents hemolysis. Given intravenously every 8 weeks. Another monoclonal antibody against C5, eculizumab is given every 2 weeks. It carries a black box warning of risk of meningococcal infection / sepsis. Therefore patient should be vaccinated for meningococcal disease. VOXELOTOR is used for oral treatment of sickle cell anemia. GIVOSIRAN is used for Acute hepatic prophyria.', 'role': 'assistant'}]